Key facts
- This page summarizes Eugene Schneider's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Jan 2022, 19:16.
Eugene Schneider - 18 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP, Chf Clinical Develop Offc
- Issuer ticker
- IONS
- Reported as of
- 18 Jan 2022
- Net transaction value
- -$114,908
- SEC form
- 4
- Accepted by SEC
- 20 Jan 2022, 19:16:14 UTC
- Prior SEC filing
- 19 Jan 2022
- Next SEC filing
- 18 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eugene Schneider filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 20 Jan 2022.
Change
- Previous filing in this sequence was filed on 19 Jan 2022.
- Current net transaction value: -$114,908.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +10,400
- Change %
- +145%
- Price
- $0.000000
- Shares after
- 17,575
- Date
- 18 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
IONS
transaction
Common Stock
Tax liability
- Transaction value
- $114,908
- Shares
- -3,815
- Change %
- -22%
- Price
- $30.12
- Shares after
- 13,760
- Date
- 18 Jan 2022
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -10,400
- Change %
- -22%
- Price
- $0.000000
- Shares after
- 36,325
- Date
- 18 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,400
- Exercise price
- $0.000000
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
Footnote F2
Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Footnote F3
Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
Footnote F4
Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.